These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6653652)

  • 21. Long-term effects of pinacidil in hypertensive dialysis patients.
    Breen EG; Mulhall D; Keogh JA
    Eur J Clin Pharmacol; 1985; 28(4):375-80. PubMed ID: 4029243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long term haemodynamic effects of pinacidil and hydralazine in arterial hypertension.
    Carlsen JE; Jensen HA; Rehling M; Lund JO; Trap-Jensen J
    Drugs; 1988; 36 Suppl 7():55-63. PubMed ID: 3076136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.
    Koliopoulos K; Papadoyannis DE; Karatzas NB
    Eur J Clin Pharmacol; 1984; 27(3):287-9. PubMed ID: 6510455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular effects of pinacidil and propranolol alone and in combination in normal humans.
    Nicholls DP; McNeill J; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1986; 8(1):51-4. PubMed ID: 2419692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics and pharmacokinetics of pinacidil in normotensive volunteers after repeated doses of a new slow-release tablet formulation.
    Bareggi SR; Gambaro V; Valenti M; Benvenuti C
    Arzneimittelforschung; 1999 Jan; 49(1):21-5. PubMed ID: 10028374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accumulation of pinacidil N-oxide during chronic treatment with pinacidil.
    McBurney A; Henry JA; Ward JW
    Eur J Clin Pharmacol; 1988; 35(1):93-5. PubMed ID: 3220100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of long-acting pinacidil on intra-arterial blood pressure.
    Caruana MP; Al-Khawaja I; Royston P; Raftery EB
    Br J Clin Pharmacol; 1985 Aug; 20(2):140-3. PubMed ID: 4041331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacology of pinacidil, a prototype for drugs that affect potassium channels.
    Goldberg MR
    J Cardiovasc Pharmacol; 1988; 12 Suppl 2():S41-7. PubMed ID: 2466178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double-blind comparator trials with pinacidil, a potassium channel opener.
    Callaghan JT; Goldberg MR; Brunelle R
    Drugs; 1988; 36 Suppl 7():77-82. PubMed ID: 3076139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic effects of direct vasodilation (pinacidil), alpha-adrenergic blockade (prazosin) and angiotensin-converting enzyme inhibition (captopril) in systemic hypertension.
    Izzo JL; Licht MR; Smith RJ; Larrabee PS; Radke KJ; Kallay MC
    Am J Cardiol; 1987 Aug; 60(4):303-8. PubMed ID: 2887102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative trial of pinacidil versus prazosin in mild to moderate arterial hypertension.
    Sterndorff B; Johansen P
    Drugs; 1988; 36 Suppl 7():64-6. PubMed ID: 3076137
    [No Abstract]   [Full Text] [Related]  

  • 32. Effects of pinacidil on serum lipid, lipoprotein, and apolipoprotein levels in patients with mild to moderate hypertension.
    Saku K; Ying H; Arakawa K
    Clin Ther; 1990; 12(2):132-8. PubMed ID: 2354482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
    Weisser B; Gerwe M; Braun M; Funken C
    Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.
    Carlsen JE; Kardel T; Hilden T; Tangø M; Trap-Jensen J
    Clin Physiol; 1981 Aug; 1(4):375-84. PubMed ID: 7199409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacokinetics of pinacidil, a potassium channel opener, in hypertension.
    Goldberg MR; Rockhold FW; Thompson WL; DeSante KA
    J Clin Pharmacol; 1989 Jan; 29(1):33-40. PubMed ID: 2708546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic model of the haemodynamic effects of pinacidil in normotensive volunteers.
    Girard P; Saumet JL; Dubois F; Boissel JP
    Eur J Clin Pharmacol; 1993; 44(2):177-82. PubMed ID: 8453963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of formulation on the pharmacokinetics of orally administered pinacidil in humans.
    McBurney A; Farrow PR; Ward JW
    J Pharm Sci; 1987 Dec; 76(12):940-1. PubMed ID: 3440941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive efficacy of a slow release nifedipine tablet formulation given once daily in patients with mild to moderate hypertension. A placebo-controlled, double-blind parallel-group trial.
    Harder S; Rietbrock S; Thürmann P
    Arzneimittelforschung; 1994 Feb; 44(2):133-6. PubMed ID: 8147945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.
    Steensgaard-Hansen F; Carlsen JE
    Drugs; 1988; 36 Suppl 7():70-6. PubMed ID: 3254831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.